Canadian application, no grantCanada
Therapy
CA 2368285 A1 · Owner: Astrazeneca Ab · Inventors: Bayati, Alfred
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invenrinn features a merhod of identifying a candidate drug for treating functional, dyspepsia. The invenrinn also features a method of diagnosing a patient with functional, dyspepsia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 17, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJanuary 17, 2002
GrantedNo grant recorded
Term endedJanuary 17, 2022
Patent numberCA 2368285 A1
Classification (IPC)A61K38/26 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.